Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer
Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer
Cancer Services Delivery: Focus on India
Intratumoral BO-112 with pembrolizumab shows benefit in advanced melanoma refractory to anti-PD-1 therapy
Maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma
Update on the new EUSOMA quality indicators for breast cancer
The optimal approach after neoadjuvant treatment: The Lucerne toolbox
OncoAlert Colloquium Day 6: Gynaecological oncology, IGCS and ESO
OncoAlert Colloquium Day 5: SWOG, OncoAlliance and more
OncoAlert Colloquium Day 4: GI oncology and EONS
OncoAlert Colloquium Day 3: Breast cancer
OncoAlert Colloquium Day 2: Lung cancer and MASCC
OncoAlert Colloquium Day 1: Genitourinary cancers and geriatric oncology